Kornimate/medical-research-clean huggingface dataset:
establishment and evaluation to the effects of a clinical pathway for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: the purpose of this study is to determine whether the clinical pathway for acute ischemic stroke(with combination of traditional chinese medicine and western medicine) is able to improve the outcome of acute ischemic stroke and evaluate its effect on hospital day and cost, etc. meanwhile, the study will discuss the safety and efficiency of this kind of clinical pathway

eligibility ages eligible for study: 18 years to 85 years genders eligible for study: both accepts healthy volunteers: no criteria inclusion criteria: those clinically diagnosed with acute ischemic stroke ； 18-85 years old； over 6 hours and within 14 days from onset 4\<=nihss \<=22; informed consent signed by patient or his/her family ； exclusion criteria: hemorrhagic stroke; cerebral hernia; serious heart, liver, lung, kidney functional failure，malignancy; not cooperative with physician; psychological disorder; already taken part in other clinical drug trial within the past 3 months

Eligibility criteria:
inclusion criteria: * ischemic stroke diagnosed with both criteria of traditional chinese medicine and western medicine； * 18-85 years old； * over 6 hours and within 14 days from onset * 4\<=nihss \<=22; * informed consent signed by patient or his/her family ； exclusion criteria: * hemorrhagic stroke; * cerebral hernia; * serious heart, liver, lung, kidney functional failure,malignancy; * not cooperative with physician; * psychological disorder; * already taken part in other clinical drug trial within the past 3 months

Keywords: acute ischemic stroke；clinical pathway;tcm；
the experience of the child with cancer when port à cath needle : child's speech

Conditions: Pediatric Oncology

Summary: this qualitative research refers to the descriptive phenomenological method of hurssel which allows an analysis of the experience and an understanding of the phenomenon. semi-structured interviews are carried out with 10 children followed for cancer in 3 pediatric hemato-oncology departments. the children interviewed are aged 6 to 12 and can be with their parents. a thematic analysis approach is used to analyze the data of this research.


Eligibility criteria:
inclusion criteria: * child followed in pediatric oncology for cancer or hematological disease * child wearing a port-a-cath needle placement and minimum use once a week exclusion criteria: * child no speaking the french language

Keywords: pediatrics; cancer; care; experience; port-a-cath
efficacy and safety study of ozanimod in ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to determine whether rpc1063 is effective in the treatment of ulcerative colitis (uc).


Eligibility criteria:
inclusion criteria: * ulcerative colitis (uc) confirmed on endoscopy * moderately to severely active uc (mayo score 6-12) exclusion criteria: * current use of anti-tnf agents
cycle and stroke with biofeedback for power symmetry

Conditions: Stroke

Summary: to determine changes in power symmetry, gait symmetry, and functional outcomes for participants' poststroke (inpatient rehabilitation facility) after participating in an intervention using a recumbent cycle with power biofeedback (bfb). to determine how this intervention can impact gait asymmetry, a common disorder poststroke secondary to hemiparesis. gait asymmetry is a difficult impairment to treat because it is difficult for both therapists and patients to perceive. training with bfb allows for quantitative data about the power production or lack of that directly impacts safety in walking, increased energy expenditure, and decreased gait speed.

specific aim 1 will determine the change in cycling power using bfb on a group of participants with stroke in an inpatient rehabilitation facility. specific aim 2 will determine the effect size of the change in gait symmetry with cycling training with power bfb pre- to post-cycle intervention. specific aim 3 will determine the effect size of the change in functional mobility with cycling training with power bfb pre- to post-cycle intervention. understanding the impact of cycle training with power bfb is an important step in improving stroke rehabilitation. this study is significant because it will provide data about power asymmetries in participants' early post-acute stroke and the transfer of training with power bfb to gait impairments.

Eligibility criteria:
inclusion criteria: 1. they have a confirmed mca or aca ischemic or intracerebral hemorrhagic stroke, confirmed by ct/mri or clinical documentation -and demonstrating lower extremity hemiparesis \[\< 100 on lower limb motricity index24\] 2. 18 to 70 years of age 3. a functional ambulation category of 2 (dependent level ii) through 5 (independent level surfaces only) 4. medical clearance to participate exclusion criteria: 1. contractures that limit lower limb range of motion 2. cardiovascular, respiratory or metabolic instability, including unstable angina or hypertension above 200/110 at rest 3. uncontrolled diabetes 4. severe respiratory disorders that limit exercise 5. inability to ambulate \> 150 feet prior to stroke 6. prior history of peripheral or central nervous system injury 7. moderate to severe hemispatial neglect according to the kessler foundation neglect assessment 8. major cognitive impairment preventing the capability to understand training instructions; identified by inability to follow 3-step command 9. severe aphasia preventing communication with the therapist.

Keywords: cycling power inpatient rehabilitation biofeedback gait symmetry
a study of the bioequivalence of 70 mg alendronate and 70 mg alendronate in combination with 2800 iu vitamin d

Conditions: Osteoporosis

Summary: this study will evaluate the bioequivalence of alendronate in combination with vitamin d (cholecalciferol) compared to alendronate alone and the bioequivalence of vitamin d in combination with alendronate compared to vitamin d alone.


Eligibility criteria:
inclusion criteria: * male or nonpregnant female age 18 to 65 years * female of childbearing potential on appropriate method of contraception and not nursing * bmi (body mass index) less than or equal to 30 kg/m2 * subject is in good health * willing to limit direct sunlight and apply sunscreen if in the sun more than 1 hour exclusion criteria: * mental or legal incapacitation * received bisphosphonate treatment within 3 months of screening * unable to sit or stand upright for at least 2 hours
comparing visual acuity measurements (how well you can see) using a standard etdrs chart & a handheld etdrs chart

Conditions: Diabetic Retinopathy

Summary: comparing visual acuity measurements (measurements of how well you can see) using a standard etdrs (early treatment diabetic retinopathy study) chart and a handheld etdrs chart

prospective determination of agreement between standard etdrs chart and handheld illuminated etdrs equivalent chart in eyes with retinal pathology

Eligibility criteria:
inclusion criteria: 1. ability to provide written informed consent and comply with study assessments for the full duration of the study (one visit per patient). 2. age greater than 18 years. 3. clinical diagnosis of retinal disease (including age-related macular degeneration, macular degeneration, retinal vessel occlusion, among others). exclusion criteria: 1. presence of a significant cataract as determined by your doctor. 2. presence of a significant posterior capsular opacity (haziness in your eyes) as determined by your doctor. 3. diagnosis of uveitis (inflammation in part of the eye).
pet/mri as a predictor of response to pre-op chemoradiation in resectable rectal cancer: a pilot study

Conditions: Rectal Carcinoma

Summary: this is a single arm, single center pilot study of 40 patients with ut3n0 or ut1-3n+ rectal cancer receiving pre-operative chemoradiation. subjects will undergo pet/mri scans before and after surgery.

the primary purpose of this study is to determine the negative predictive value of pet/mri for determining pathological complete response from neoadjuvant chemoradiation.

Eligibility criteria:
inclusion criteria: * low-lying, low- to moderate-risk pathologically-confirmed rectal cancer (stage ut3n) or ut1-3n+ * negative workup for distant disease * \> 18 years of age * pre-treatment workup completed including: * history and physical * ct or mri of the abdomen and pelvis * endoscopic tumor evaluation (biopsy, blood work to assess cea and hematopoietic, renal and liver function) * if female of child-bearing age, negative pregnancy test * recommendation to undergo preoperative concurrent chemoradiation, as determined by the treating physician * informed consent reviewed and signed exclusion criteria: * not deemed a candidate for preoperative chemoradiation for medical reasons, such as uncontrolled infection (including hiv), uncontrolled diabetes mellitus or cardiac disease * hemoglobin ≤ 10.0 g/dl (transfusion allowed to achieve or maintain levels) * anc ≤ 1,500/cubic mm³ * platelet count ≤ 100,000/mm³ * alt and ast ≥ 2.5 times upper level of normal (uln) * alkaline phosphatase ≥ 2.5 times uln * total bilirubin ≥ 1.5 times uln * creatinine clearance \< 50 ml/min * creatinine ≥ 1.5 times uln * not deemed a candidate for concurrent preoperative chemoradiation for social reasons, such as psychiatric illness * not deemed a surgical candidate * currently active second malignancy, except non-melanoma skin cancer, non-invasive bladder cancer, low risk adenocarcinoma of the prostate and carcinoma in situ of the cervix * previous pelvic radiation therapy * history of severe reaction to gadolinium * inability to tolerate mri (e.g., inability to lie flat for \> 1 hour) * presence of a pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes * body mass index (bmi) \> 35 * pregnant or lactating female
a study to describe the persistence with ozanimod treatment in relapsing-remitting multiple sclerosis (rrms) participants

Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Summary: the purpose of the study is to collect clinical data on the persistence with ozanimod treatment, as well as to describe its effects on participant-relevant outcome parameters in treatment-naïve participants with rrms.


Eligibility criteria:
inclusion criteria: * relapsing-remitting multiple sclerosis (rrms) diagnosis by 2017 revised mcdonald criteria at the treatment start * participant who started treatment with ozanimod for the first time 3 months (+/- 2 weeks) before inclusion, according to european union (eu) summary of product characteristics (smpc) and/or spanish therapeutic positioning report (tpr) recommendation and following routine clinical practice of the participating hospital * low-to-moderate activity, defined as less than 2 relapses in the previous year before starting the treatment with ozanimod exclusion criteria: * prior exposure to ozanimod or any other disease modifier treatment (dmt) for rrms before starting treatment with ozanimod subject of this study * participant who has started ozanimod within a clinical trial note: other protocol-defined inclusion/exclusion criteria apply

Keywords: ozanimod zeposia relapsing-remitting multiple sclerosis
safety, tolerability, and pharmacokinetics of asc43f, a fixed dose combination tablet in healthy subjects

Conditions: Healthy Volunteer

Summary: this is a phase 1, open-label study in healthy adults. this study is aimed at evaluating the safety, tolerability, and pharmacokinetics of asc43f, a fixed-dose combination (fdc) and single dose tablet containing asc41, a thr β agonist and asc42, an fxr agonist in healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects between 18 to 65 years of age. * subjects must weigh at least 50 kg (110 pounds \[lbs.\]) for men, and at least 45 kg (99 lbs.) for women and body mass index (bmi) within the range 18.5-32 kilogram per meter square (kg/m2). * physical examination and vital signs are within normal range or slightly abnormal. exclusion criteria: * any surgical or medical condition which in the opinion of the investigator, might significantly alter the absorption, distribution, metabolism, or excretion of drugs. * abnormal clinical or laboratory findings that indicate diseases including but not limited to renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic disease. * history or current electrocardiogram (ecg) abnormalities, arrhythmias or heart valve diseases. * history of viral hepatitis or hiv * history of drug or food allergies that caused severe hypersensitivity reactions or anaphylaxis.).

Keywords: asc43f phase 1 thyroid hormone receptor beta agonist fxr agonist asc41 asc42
the correlation between pupil size and retinal nerve fibers changes in pseudoexfoliation syndrome.

Conditions: Pseudoexfoliation Syndrome

Summary: to study the possible correlation between pupillary diameter before and after dilation with intraocular pressure, lens stability and glaucomatous damage (represented by optic disc changes using cup to disc ratio and oct changes in retinal nerve fiber layer and ganglion cell complex) in each eye of the same patient with pex.

pseudoexfoliation (pex) is a widespread condition that is often considered as a generalized disorder involving ocular manifestations as well as other body systems. it is characterized by the deposition of a distinctive fibrillar material in the anterior segment of the eye. the effect of pseudoexfoliation on various ocular tissues has been well studied in the past decades, especially both lens and optic disc damage. key signs in pseudoexfoliative eyes are attributed to the effect of pseudoexfoliation material on pupillary muscles, lens and optic disc. pseudoexfoliation appears to be a common disorder in older individuals in upper egypt with a prevalence of 4.14%. pxf was bilateral in 82.2% of cases. it was significantly associated with cataract, glaucoma and hearing loss. of the pxf patients, 65% had cataract, 30.3% had glaucoma and 8.1% had hearing loss. cardiovascular and cerebrovascular diseases such as angina, aortic aneurysm, and dementia have been linked to pxs. subjects with pxf had a two- to three-fold increased risk for glaucoma according to the blue mountains eye study. the classic sign of pxf is the visualization of white pseudoexfoliative material on the pupil margin and on the anterior lens surface. it is believed that pupil size is another indicator for the severity of the disease. in this study we correlate the pupil size with other common ocular signs in pex such as; lens subluxation and glaucomatous damage.

Eligibility criteria:
inclusion criteria: * all patients with pseudoexfoliation syndrome. exclusion criteria: * previous ocular surgery or ocular trauma affecting the pupil. any systemic or neurologic disease affecting the pupil

Keywords: pupil pseudoexfoliation pupil dilation pupil size pseudoexfoliation syndrome
evaluation of therapeutic plasma exchange (tpe) procedure using the amicus device

Conditions: Autoimmune Diseases; Renal Disorders; Hematologic Disorders; Oncologic Disorders

Summary: this study will evaluate the use of the amicus device in patients where therapeutic plasma exchange (tpe) is prescribed by their physicians.

therapeutic plasma exchange (tpe) is intended for efficient removal of circulating plasma, with the return of replacement fluids to the patient. in the majority of cases, the treatment goal is to selectively remove the substance directly responsible for the patient's disease process. fenwal's amicus separator platform is a centrifuge-based apheresis system which collects the blood components of interest and returns the remaining blood components along with saline back to a donor/patient. the device has been cleared for the following: * the collection of platelets and plasma in japan, europe and the us (bk960005), 1996. * the collection of mononuclear cells (mncs) in the us (bk000047), 2002. * the collection of a concurrent red blood cell (crbc) product collected in acd-a anticoagulant and stored in adsol® preservation solution (bk000039), 2002. fenwal has developed a new protocol on the amicus separator that enables the device to perform tpe procedures. the procedure is similar to the fda cleared platelet and concurrent plasma collections, except that in tpe procedures the majority of plasma is retained and the red blood cells (rbcs), white blood cells (wbc) and the majority of the platelets are returned to the patient.

Eligibility criteria:
inclusion criteria: 1. medically stable patients undergoing more than one tpe procedure who have provided signed informed consent prior to participation. 2. a physician's prescription for tpe for various non-emergent conditions. 3. test and control tpe procedures that would be expected to be completed within approximately five weeks. exclusion criteria: 1. patients under 18 years old. 2. patients on an ace inhibitor medication should discontinue use of this medication in accordance with institutional practices. 3. patients with altered mental status that would prohibit the giving and understanding of informed consent. 4. patients who have experienced a serious adverse event associated with the first tpe clinical study procedure.

Keywords: therapeutic plasma exchange autoimmune diseases kidney transplant hematologic disorders monoclonal gammopathy neurologic disorders
meniscus repair with simultaneous acl reconstruction: clinical outcomes，failure rates and subsequent processing

Conditions: The ACL Rupture; Meniscus Injury

Summary: our study has explored the causes of failure of meniscus repair and investigated the clinical effects of partial meniscectomy when meniscus repair failed.

background: meniscus repair performed during acl reconstruction may fail and the subsequent treatment includes revision meniscal repair or partial meniscectomy. purpose: to retrospectively analyze the clinical outcomes of meniscus repair with simultaneous anterior cruciate ligament (acl) reconstruction and explore the causes of failure of meniscus repair. methods: from may 2013 to july 2018, the clinical data of 165 patients who were treated with meniscus surgery and simultaneous acl reconstruction by the same doctor, including 69 cases of meniscus repair (repair group) and 96 cases of partial meniscectomy (partial meniscectomy group), were retrospectively analyzed. the 69 patients of the repair group were divided into the nonfailure group (62 cases) and the failure group (7 cases) depending on the repair effect. the average follow-up period was 38 (±10.5) months. postoperative outcomes of the repair group and the partial meniscectomy group were compared. general conditions and postoperative outcomes of the failure group and the nonfailure group were compared. seven patients in the failure group who underwent second arthroscopy were followed up for 30 (±17.4) months, and their postoperative outcomes were summarized.

Eligibility criteria:
inclusion criteria: 1. patients with intraoperatively confirmed acl rupture combined with medial, lateral, or medial and lateral meniscal injury; 2. age \<60 years 3. no history of previous ipsilateral knee meniscal injury. exclusion criteria: 1. acl rupture associated with fracture, collateral ligament injury, or complex ligament injury; 2. a history of knee surgery; 3. a significant degree of osteoarthritis.

Keywords: meniscus failure of repair anterior cruciate ligament reconstruction arthroscopy
safety and efficacy study of tak-700 in patients with nonmetastatic castration-resistant prostate cancer and a rising prostate-specific antigen

Conditions: Prostate Cancer

Summary: this is a multicenter phase 2 open-label single-arm study that will evaluate the safety and efficacy of tak-700 in patients with castration-resistant prostate cancer (crpc) without radiographic evidence of metastases who have a rising prostate-specific antigen (psa).


Eligibility criteria:
inclusion criteria: each patient must meet all of the following inclusion criteria: * male patients 18 years or older * eastern cooperative oncology group performance status 0-2 * male patients who practice effective barrier contraception during study and for 4 months after the last dose of study drug, or abstain from heterosexual intercourse. * voluntary written consent * histologically or cytologically confirmed diagnosis of prostate adenocarcinoma without radiographic evidence of metastasis but with a rising psa during or following the patient's most recent antineoplastic therapy despite castrate concentrations of testosterone * baseline psa must be greater than or equal to 2 ng/ml and psa doubling time must be less than or equal to 8 months or baseline psa must be greater than or equal to 8 ng/ml if psa doubling time is greater than 8 months * has undergone orchiectomy or will continue receiving gnrh analogue therapy * meet screening laboratory values as specified in protocol exclusion criteria: patients meeting any of the following exclusion criteria are not to be enrolled in the study: * known hypersensitivity to tak-700 or related compounds * received any of the following within 30 days prior to the first dose of tak-700: any investigational compound; prior herbal product known to decrease psa; radiation therapy for prostate cancer; or chronic therapy with corticosteroids * received prior therapy with aminoglutethimide or ketoconazole * received antiandrogen therapy within 4 weeks for flutamide and 6 weeks for all others prior to first dose of study drug * received prior chemotherapy for prostate cancer * current bladder neck outlet obstruction caused by prostate cancer, current spinal cord compression, or current bilateral hydronephrosis * symptoms that investigator deems related to prostate cancer * diagnosis or treatment of another malignancy within 2 years preceding first dose of study drug except nonmelanoma skin cancer or in situ malignancy completely resected * history of adrenal insufficiency * uncontrolled cardiovascular condition * known history of human immunodeficiency virus (hiv) infection, hepatitis b, or hepatitis c * unwilling or unable to comply with protocol * major surgery or serious infection within 14 days of first dose of tak-700 * life-threatening illness unrelated to cancer * uncontrolled nausea, vomiting or diarrhea * known gastrointestinal disease or procedure that could interfere with oral absorption or tolerance of tak-700
psychosocial factors and quality of life in the effect of fear of covid-19 with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the purpose of this study; the covid-19 pandemic is to investigate the effects of covid-19 fear levels of patients with cystic fibrosis on the psychosocial and quality of life levels of individuals.

after individuals were informed about the study, it was administered to individuals who gave written informed consent.this study was carried out on individuals with cystic fibrosis and healthy individuals who meet the eligibility requirements, through online forms.

Eligibility criteria:
inclusion criteria: * be 16 years of age or older * having been diagnosed with cystic fibrosis * volunteering to participate in the research exclusion criteria: * being mentally incapable of successfully applying the scales to be applied for evaluation purposes * being treated with sedative and antiepileptic drugs * pregnancy
combined vibrations, passive motion and thermotherapy for knee osteoarthritis

Conditions: Osteoarthritis; Knee Pain

Summary: the study evaluated the efficacy of combined mechanical vibrations, continuous passive motion and heat on the severity of pain in management of osteoarthritis of the knee


Eligibility criteria:
inclusion criteria: * diagnosis of oa of the knee by acr criteria * symptoms consistent with radiographic oa grades 2, 3 or 4 by kellgren and lawrence criteria * moderate to severe knee pain (≥35mm on a 100mm visual analog pain scale (vas)). exclusion criteria: * knee or hip surgery